These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11385441)

  • 1. Biotechnology Texas style.
    Mehrens D; Hart S
    Nat Biotechnol; 2001 Jun; 19(6):510-2. PubMed ID: 11385441
    [No Abstract]   [Full Text] [Related]  

  • 2. Thinking big Texas.
    Gershon D
    Nature; 2005 Apr; 434(7037):1160-1. PubMed ID: 15858579
    [No Abstract]   [Full Text] [Related]  

  • 3. A window of opportunity.
    McCormick D; Hodgson J
    Nature; 1993 Oct; 365(6447):676-8. PubMed ID: 8413633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drivers of health care costs: technology vs social, legal, and behavioral factors.
    Thrall JH
    J Am Coll Radiol; 2009 Jun; 6(6):387-8. PubMed ID: 19467479
    [No Abstract]   [Full Text] [Related]  

  • 5. The biotechnology bubble machine.
    Rasnick D
    Nat Biotechnol; 2003 Apr; 21(4):355-6. PubMed ID: 12665813
    [No Abstract]   [Full Text] [Related]  

  • 6. US venture capital for biotechnology.
    Dibner MD; Trull M; Howell M
    Nat Biotechnol; 2003 Jun; 21(6):613-7. PubMed ID: 12776144
    [No Abstract]   [Full Text] [Related]  

  • 7. Evolving symbiosis--venture capital and biotechnology.
    Bradford TC
    Nat Biotechnol; 2003 Sep; 21(9):983-4. PubMed ID: 12949556
    [No Abstract]   [Full Text] [Related]  

  • 8. The biotechnology industry: What's next?
    Guertin PA
    Biotechnol J; 2009 Aug; 4(8):1124-31. PubMed ID: 19685466
    [No Abstract]   [Full Text] [Related]  

  • 9. Public biotechnology 2001--the numbers.
    Lähteenmäki R; Fletcher L
    Nat Biotechnol; 2002 Jun; 20(6):551-5. PubMed ID: 12042853
    [No Abstract]   [Full Text] [Related]  

  • 10. Partnering up in Q3.
    Lawrence S
    Nat Biotechnol; 2007 Nov; 25(11):1200. PubMed ID: 17989659
    [No Abstract]   [Full Text] [Related]  

  • 11. Bioterrorism--biotechnology to the rescue?
    Niiler E
    Nat Biotechnol; 2002 Jan; 20(1):21-5. PubMed ID: 11753354
    [No Abstract]   [Full Text] [Related]  

  • 12. US government previews biotech survey.
    Goho A
    Nat Biotechnol; 2003 Aug; 21(8):837-8. PubMed ID: 12894185
    [No Abstract]   [Full Text] [Related]  

  • 13. Biotechnology and sustainability: the role of transatlantic cooperation in research and innovation.
    Aguilar A; Bochereau L; Matthiessen-Guyader L
    Trends Biotechnol; 2008 Apr; 26(4):163-5. PubMed ID: 18295918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fickle financing climate continues.
    Mitchell P
    Nat Biotechnol; 2001 Aug; 19(8):695-6. PubMed ID: 11479542
    [No Abstract]   [Full Text] [Related]  

  • 15. Public biotechnology 2002--the numbers.
    Lähteenmäki R; DeFrancesco L
    Nat Biotechnol; 2003 Jun; 21(6):607-12. PubMed ID: 12776143
    [No Abstract]   [Full Text] [Related]  

  • 16. Delisting threat looms large on biotech front.
    Lawrence S
    Nat Biotechnol; 2005 Jan; 23(1):5. PubMed ID: 15637598
    [No Abstract]   [Full Text] [Related]  

  • 17. Setbacks for blood substitute companies.
    Niiler E
    Nat Biotechnol; 2002 Oct; 20(10):962-3. PubMed ID: 12355103
    [No Abstract]   [Full Text] [Related]  

  • 18. The view from the top.
    Howard K
    Nature; 2003 Dec; 426(6967):696-7. PubMed ID: 14668873
    [No Abstract]   [Full Text] [Related]  

  • 19. Public biotechnology 2005--the numbers.
    Lähteenmäki R; Lawrence S
    Nat Biotechnol; 2006 Jun; 24(6):625-34. PubMed ID: 16763588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shutters come off IPO window.
    Hodgson J
    Nat Biotechnol; 2002 Jan; 20(1):6. PubMed ID: 11753342
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.